Brief: Beyondspring Announces First Patient Dosed In A Triple Combination Study To Treat Advanced Solid Tumors
04/06/2021 12:15
June 4 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES FIRST PATIENT DOSED IN A TRIPLE
COMBINATION STUDY WITH PLINABULIN, PD-1/PD-L1 INHIBITOR AND
RADIOTHERAPY FOR THE REVERSAL OF RESISTANCE TO PD-1/PD-L1
INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX7xlS8F
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value